Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
3(10%)
Results Posted
0%(0 trials)
Terminated
3(10%)

Phase Distribution

Ph not_applicable
15
52%
Ph phase_1
3
10%
Ph phase_2
8
28%

Phase Distribution

3

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
3(11.5%)
Phase 2Efficacy & side effects
8(30.8%)
N/ANon-phased studies
15(57.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

56.3%

9 of 16 finished

Non-Completion Rate

43.8%

7 ended early

Currently Active

3

trials recruiting

Total Trials

29

all time

Status Distribution
Active(6)
Completed(9)
Terminated(7)
Other(7)

Detailed Status

Completed9
unknown7
Withdrawn4
Terminated3
Not yet recruiting3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
29
Active
3
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (11.5%)
Phase 28 (30.8%)
N/A15 (57.7%)

Trials by Status

unknown724%
completed931%
withdrawn414%
terminated310%
not_yet_recruiting310%
recruiting310%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT06378047Phase 1

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Completed
NCT07306273Phase 2

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

Recruiting
NCT03080974Phase 2

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
NCT07192731Not Applicable

International Study on Treatment of Liver (HCC) Patients With IRE

Not Yet Recruiting
NCT07191548Not Applicable

International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE

Not Yet Recruiting
NCT04972097Not Applicable

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

Completed
NCT06677762

Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer

Not Yet Recruiting
NCT06185556Phase 2

COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases

Recruiting
NCT05609656Phase 2

Electroporation and Immunotherapy in Metastatic Colorectal Cancer

Terminated
NCT03257150Not Applicable

A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer

Completed
NCT04717687Not Applicable

Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma

Withdrawn
NCT04835402Phase 2

Electroporation Potentiated Immunotherapy in Cancer

Unknown
NCT03673137Phase 2

Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC

Completed
NCT02335827Not Applicable

Irreversible Electroporation(IRE) For Unresectable Renal Tumors

Completed
NCT03337997Not Applicable

A Pilot Study of IRE for Resectable Pancreatic Cancer

Withdrawn
NCT04404647Not Applicable

Irreversible Electroporation of Unresectable Liver Tumors

Withdrawn
NCT02981719Not Applicable

Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Completed
NCT03040453Not Applicable

Immunological Response After Ablative Therapy in the Liver

Withdrawn
NCT04310553Not Applicable

An Open-label, Multicenter, Prospective Study of Irreversible Electroporation (Nano Knife) Combined With Radiotherapy and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Unknown
NCT02926040

Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer

Terminated

Drug Details

Intervention Type
DEVICE
Total Trials
29